Roche, Blueprint Medicines sign $1.7bn worth deal for pralsetinib
The deal gives Roche exclusive rights for the co-development and commercialisation of pralsetinib outside the US with the exclusion of Mainland China, Hong Kong, Macau, and Taiwan. In
Exegenesis Bio and Modalis Therapeutics have entered a research partnership and licence agreement to progress MDL-201, a therapeutic candidate for Duchenne muscular dystrophy (DMD).
The two of the firms’ four investigational vaccine candidates from their BNT162 mRNA-based vaccine programme, including BNT162b1 and BNT162b2, are being developed to treat SARS-CoV-2. BioNTech chief medical
The first group of volunteers who were administered the coronavirus vaccine candidate will be discharged this week, reported Sputnik, citing the university’s Institute for Translational Medicine and Biotechnology
The companies will also partner on a second earlier stage program. Kymera will receive $150 million in cash upfront and may receive more than $2 billion in potential development, regulatory and sales
The EC approval allows using Lynparza as a maintenance treatment for adult patients with germline BRCA1/2 mutations who have metastatic adenocarcinoma of the pancreas and have not progressed